Liver Int:高γ-球蛋白血症是代偿性肝硬化患者疾病进展、HCC发生和死亡的预测因素

2017-12-11 MedSci MedSci原创

:高γ-球蛋白血症是Child-Pugh (C-P)A级肝硬化患者疾病进展、HCC发生和死亡的预测因素。

代偿性肝硬化的结果可能会有很大的差异,目前还不能通过常规的测试来预测疾病进展。本研究通过分析诊断时以及随后长期随访过程中,临床/生化/仪器参数,旨在在Child-Pugh (C-P)A级肝硬化患者中寻找可能能够预测临床演变的因素。

研究方法:272例连续检测为Child-Pugh (C-P)A级肝硬化患者(155例男性患者,平均年龄63岁,年龄范围为:34-81岁)。所有患者随访中位时间均为96个月(范围:21-144个月)。定期进行临床/生化/超声和消化道检测。

研究结果:在随访过程中,97例(36%)患者病情稳定,104例(36%)患者发生肝细胞癌(HCC),71例(26%)患者进展到Child-Pugh B/C级(并没有发生HCC)。131例患者(48%)死亡或进行肝移植。多元回归分析表明,临床病情稳定与高龄(p<0.001),无糖尿病(p=0.04),无食管静脉曲张(p<0.001),血清白蛋白>3.5 gr/dl (p=0.01),γ-球蛋白<1.8 gr/dl (p=0.01)显著相关。HCC与低龄(p=0.01),血清γ-球蛋白值≥1.8 gr/dl (p<0.001)显著相关。C-P分数进展与食管静脉曲张(p<0.001)、低血清白蛋白(p=0.03)和胆固醇(p=0.01),高γ-球蛋白血症(p=0.02)显著相关。死亡与低龄(p<0.001)和高γ-球蛋白血症(p=0.01)显著相关。多元回归分析和Kaplan-Meier's生存测试表明,γ-球蛋白≥1.8 g/dl是死亡的预测因素(P分别为p<0.02和p<0.01)。

研究结论:高γ-球蛋白血症是Child-Pugh (C-P)A级肝硬化患者疾病进展、HCC发生和死亡的预测因素。

原始出处

Cacciola I, Filomia R, Alibrandi A, et al. Hypergammaglobulinemia is a strong predictor of disease progression, hepatocellular carcinoma, and death in patients with compensated cirrhosis. Liver Int, 2017, Dec 1. doi: 10.1111/liv.13649.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2077553, encodeId=612620e7553fc, content=<a href='/topic/show?id=94c7253e768' target=_blank style='color:#2F92EE;'>#代偿性肝硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25377, encryptionId=94c7253e768, topicName=代偿性肝硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Aug 26 21:03:00 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907685, encodeId=c193190e685f5, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Fri Jun 08 20:03:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035158, encodeId=9278203515820, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Dec 19 03:03:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259495, encodeId=f6d8125949500, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 13 13:03:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264266, encodeId=e2801264266bd, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Wed Dec 13 13:03:00 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2077553, encodeId=612620e7553fc, content=<a href='/topic/show?id=94c7253e768' target=_blank style='color:#2F92EE;'>#代偿性肝硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25377, encryptionId=94c7253e768, topicName=代偿性肝硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Aug 26 21:03:00 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907685, encodeId=c193190e685f5, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Fri Jun 08 20:03:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035158, encodeId=9278203515820, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Dec 19 03:03:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259495, encodeId=f6d8125949500, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 13 13:03:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264266, encodeId=e2801264266bd, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Wed Dec 13 13:03:00 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2077553, encodeId=612620e7553fc, content=<a href='/topic/show?id=94c7253e768' target=_blank style='color:#2F92EE;'>#代偿性肝硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25377, encryptionId=94c7253e768, topicName=代偿性肝硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Aug 26 21:03:00 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907685, encodeId=c193190e685f5, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Fri Jun 08 20:03:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035158, encodeId=9278203515820, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Dec 19 03:03:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259495, encodeId=f6d8125949500, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 13 13:03:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264266, encodeId=e2801264266bd, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Wed Dec 13 13:03:00 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2017-12-19 xzw113
  4. [GetPortalCommentsPageByObjectIdResponse(id=2077553, encodeId=612620e7553fc, content=<a href='/topic/show?id=94c7253e768' target=_blank style='color:#2F92EE;'>#代偿性肝硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25377, encryptionId=94c7253e768, topicName=代偿性肝硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Aug 26 21:03:00 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907685, encodeId=c193190e685f5, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Fri Jun 08 20:03:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035158, encodeId=9278203515820, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Dec 19 03:03:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259495, encodeId=f6d8125949500, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 13 13:03:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264266, encodeId=e2801264266bd, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Wed Dec 13 13:03:00 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2017-12-13 智智灵药
  5. [GetPortalCommentsPageByObjectIdResponse(id=2077553, encodeId=612620e7553fc, content=<a href='/topic/show?id=94c7253e768' target=_blank style='color:#2F92EE;'>#代偿性肝硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25377, encryptionId=94c7253e768, topicName=代偿性肝硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Aug 26 21:03:00 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907685, encodeId=c193190e685f5, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Fri Jun 08 20:03:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035158, encodeId=9278203515820, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Dec 19 03:03:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259495, encodeId=f6d8125949500, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 13 13:03:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264266, encodeId=e2801264266bd, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Wed Dec 13 13:03:00 CST 2017, time=2017-12-13, status=1, ipAttribution=)]

相关资讯

J Gastroenterol Hepatol:HBV核心相关抗原水平能够预测乙肝病毒携带者的肝硬化进展

HBcrAg水平增加,增加了疾病进展到肝硬化程度的风险。HBcrAg是肝硬化发展的良好预测指标。

Aliment Pharmacol Ther:肥胖和二型糖尿病是先前未确诊的肝硬化患者的重要危险因素

经诊断的肝硬化新病例的数量清楚地表明,现有估计的患病率可能是严重低估。肥胖是酗酒者和糖尿病患者肝硬化的一个重要危险因素。

Eur J Gastroenterol Hepatol:轻度CHB和乙型肝炎肝硬化患者间,LSM与肝纤维化相关因子间的相关性有显著差异

研究结果表明,在轻度CHB和乙型肝炎肝硬化患者间,LSM与肝纤维化相关因子间的相关性有显著差异。

NEJM:非酒精性脂肪性肝炎的成因及管理

近日,权威医学刊物《新英格兰医学》发表了一篇指导性文献《非酒精性脂肪性肝炎的成因、发病机制及治疗》。

Liver Int:新校准的MELD和肝性脑病是肝硬化患者急性静脉曲张出血的预后因素

:新校正的以MELD为基础的评分能够准确预测死亡率。内镜下出血活跃对肝硬化患者急性静脉曲张出血无预后价值。 Liver Int:新校准的MELD和肝性脑病是肝硬化患者急性静脉曲张出血的预后因素

Clin Transplant:sofosbuvir +daclatasvir联合ribavirin或不联合ribavirin治疗移植后丙肝复发和严重肝纤维化患

sofosbuvir (SOF)+daclatasvir(DCV)联合利巴韦林或不联合利巴韦林治疗存在严重肝纤维化的丙型肝炎病毒(HCV)感染的肝移植患者是有效且安全的。